Oric Pharmaceuticals (ORIC) Stock Forecast & Price Target

Compare

428 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ORIC Analyst Ratings

Strong Buy

11 Buy

1 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Oric

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ORIC Stock 12 Month Forecast

Average Price Target

$19.33

▲(133.74% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Oric Pharmaceuticals in the last 3 months. The average price target is $19.33 with a high forecast of $25.00 and a low forecast of $15.00. The average price target represents a 133.74% change from the last price of $8.27.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","15":"$15","26":"$26","9.5":"$9.5","20.5":"$20.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,9.5,15,20.5,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.15,12.215384615384616,13.28076923076923,14.346153846153847,15.411538461538463,16.47692307692308,17.542307692307695,18.607692307692307,19.673076923076923,20.73846153846154,21.803846153846152,22.869230769230768,23.934615384615384,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.15,11.77923076923077,12.408461538461538,13.037692307692307,13.666923076923077,14.296153846153846,14.925384615384615,15.554615384615383,16.183846153846154,16.81307692307692,17.44230769230769,18.07153846153846,18.70076923076923,{"y":19.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.15,11.446153846153846,11.742307692307692,12.038461538461538,12.334615384615384,12.63076923076923,12.926923076923076,13.223076923076924,13.51923076923077,13.815384615384616,14.111538461538462,14.407692307692308,14.703846153846154,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.41,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.17,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.42,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.53,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.57,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.47,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.14,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.12,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.38,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.71,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.16,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.15,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$25.00

Average Price Target$19.33

Lowest Price Target$15.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Cory Kasimov

Evercore ISI

$25

Buy

202.30%

Upside

Reiterated

12/19/25

Oric Pharmaceuticals (ORIC) Receives a Buy from Evercore ISI

David Nierengarten

Wedbush

$8.22→$20

Buy

141.84%

Upside

Reiterated

12/18/25

Wedbush Reaffirms Their Buy Rating on Oric Pharmaceuticals (ORIC)

Derek Archila

Wells Fargo

$25

Buy

202.30%

Upside

Reiterated

12/16/25

Wells Fargo Remains a Buy on Oric Pharmaceuticals (ORIC)

Matthew Biegler

Oppenheimer

$15

Buy

81.38%

Upside

Reiterated

12/08/25

Oppenheimer Sticks to Its Buy Rating for Oric Pharmaceuticals (ORIC)

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$15

Buy

81.38%

Upside

Reiterated

12/08/25

Roth MKM Reaffirms Their Buy Rating on Oric Pharmaceuticals (ORIC)

Anupam Rama

J.P. Morgan

Buy

―

Reiterated

12/07/25

Buy Rating for Oric Pharmaceuticals: Enozertinib's Promising Efficacy and Strategic Value

Soumit Roy

JonesTrading

$17→$20

Buy

141.84%

Upside

Reiterated

12/05/25

Promising Clinical Data and Market Potential Drive Buy Rating for Oric Pharmaceuticals' Enozertinib

Robert Burns

H.C. Wainwright

$19→$23

Buy

178.11%

Upside

Reiterated

11/17/25

Promising Potential of ORIC-944 in mCRPC Treatment Boosts Buy Rating and Price Target

Yigal Nochomovitz

Citi

$12→$16

Buy

93.47%

Upside

Reiterated

11/17/25

Oric Pharmaceuticals price target raised to $16 from $12 at CitiOric Pharmaceuticals price target raised to $16 from $12 at Citi

Unknown Analyst

Wolfe Research

Not Ranked

Wolfe Research

Hold

―

Initiated

11/17/25

Oric Pharmaceuticals initiated with a Peer Perform at Wolfe ResearchOric Pharmaceuticals initiated with a Peer Perform at Wolfe Research

Kevin DeGeeter

Ladenburg Thalmann & Co.

$15

Buy

81.38%

Upside

Reiterated

11/14/25

Oric Pharmaceuticals (ORIC) Gets a Buy from Ladenburg Thalmann & Co.

Prakhar Agrawal

Cantor Fitzgerald

Buy

―

Reiterated

09/26/25

Oric Pharmaceuticals (ORIC) Receives a Buy from Cantor Fitzgerald

Bradley Canino

Guggenheim

$18

Buy

117.65%

Upside

Initiated

09/03/25

Oric Pharmaceuticals' ORIC-944: A Promising PRC2 Inhibitor with Strategic Partnerships and Market Potential

Maury Raycroft

Jefferies

$22→$23

Buy

178.11%

Upside

Reiterated

08/13/25

Jefferies Reaffirms Their Buy Rating on Oric Pharmaceuticals (ORIC)

Colleen M. Kusy

Robert W. Baird

Buy

―

Reiterated

05/07/25

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Cory Kasimov

Evercore ISI

$25

Buy

202.30%

Upside

Reiterated

12/19/25

Oric Pharmaceuticals (ORIC) Receives a Buy from Evercore ISI

David Nierengarten

Wedbush

$8.22→$20

Buy

141.84%

Upside

Reiterated

12/18/25

Wedbush Reaffirms Their Buy Rating on Oric Pharmaceuticals (ORIC)

Derek Archila

Wells Fargo

$25

Buy

202.30%

Upside

Reiterated

12/16/25

Wells Fargo Remains a Buy on Oric Pharmaceuticals (ORIC)

Matthew Biegler

Oppenheimer

$15

Buy

81.38%

Upside

Reiterated

12/08/25

Oppenheimer Sticks to Its Buy Rating for Oric Pharmaceuticals (ORIC)

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$15

Buy

81.38%

Upside

Reiterated

12/08/25

Roth MKM Reaffirms Their Buy Rating on Oric Pharmaceuticals (ORIC)

Anupam Rama

J.P. Morgan

Buy

―

Reiterated

12/07/25

Buy Rating for Oric Pharmaceuticals: Enozertinib's Promising Efficacy and Strategic Value

Soumit Roy

JonesTrading

$17→$20

Buy

141.84%

Upside

Reiterated

12/05/25

Promising Clinical Data and Market Potential Drive Buy Rating for Oric Pharmaceuticals' Enozertinib

Robert Burns

H.C. Wainwright

$19→$23

Buy

178.11%

Upside

Reiterated

11/17/25

Promising Potential of ORIC-944 in mCRPC Treatment Boosts Buy Rating and Price Target

Yigal Nochomovitz

Citi

$12→$16

Buy

93.47%

Upside

Reiterated

11/17/25

Oric Pharmaceuticals price target raised to $16 from $12 at CitiOric Pharmaceuticals price target raised to $16 from $12 at Citi

Unknown Analyst

Wolfe Research

Not Ranked

Wolfe Research

Hold

―

Initiated

11/17/25

Oric Pharmaceuticals initiated with a Peer Perform at Wolfe ResearchOric Pharmaceuticals initiated with a Peer Perform at Wolfe Research

Kevin DeGeeter

Ladenburg Thalmann & Co.

$15

Buy

81.38%

Upside

Reiterated

11/14/25

Oric Pharmaceuticals (ORIC) Gets a Buy from Ladenburg Thalmann & Co.

Prakhar Agrawal

Cantor Fitzgerald

Buy

―

Reiterated

09/26/25

Oric Pharmaceuticals (ORIC) Receives a Buy from Cantor Fitzgerald

Bradley Canino

Guggenheim

$18

Buy

117.65%

Upside

Initiated

09/03/25

Oric Pharmaceuticals' ORIC-944: A Promising PRC2 Inhibitor with Strategic Partnerships and Market Potential

Maury Raycroft

Jefferies

$22→$23

Buy

178.11%

Upside

Reiterated

08/13/25

Jefferies Reaffirms Their Buy Rating on Oric Pharmaceuticals (ORIC)

Colleen M. Kusy

Robert W. Baird

Buy

―

Reiterated

05/07/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Oric Pharmaceuticals

1 Month

xxx

Success Rate

8/16 ratings generated profit

Average Return

+3.30%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +3.30% per trade.

3 Months

xxx

Success Rate

10/20 ratings generated profit

Average Return

+9.46%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +9.46% per trade.

1 Year

Robert BurnsH.C. Wainwright

Success Rate

11/20 ratings generated profit

Average Return

+13.72%

reiterated a buy rating last month

Copying Robert Burns's trades and holding each position for 1 Year would result in 55.00% of your transactions generating a profit, with an average return of +13.72% per trade.

2 Years

xxx

Success Rate

7/16 ratings generated profit

Average Return

+25.21%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 43.75% of your transactions generating a profit, with an average return of +25.21% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ORIC Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ORIC has received 23 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ORIC average Analyst price target in the past 3 months is 19.33.

Each month's total comprises the sum of three months' worth of ratings.

ORIC Financial Forecast

ORIC Earnings Forecast

Next quarter’s earnings estimate for ORIC is -$0.37 with a range of -$0.51 to -$0.30. The previous quarter’s EPS was -$0.33. ORIC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ORIC has Performed in-line its overall industry.

No data currently available

ORIC Sales Forecast

Next quarter’s sales forecast for ORIC is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ORIC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ORIC has Performed in-line its overall industry.

ORIC Stock Forecast FAQ

What is ORIC’s average 12-month price target, according to analysts?

Based on analyst ratings, Oric Pharmaceuticals’s 12-month average price target is 19.33.

What is ORIC’s upside potential, based on the analysts’ average price target?

Oric Pharmaceuticals has 133.74% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ORIC a Buy, Sell or Hold?

Oric Pharmaceuticals has a consensus rating of Strong Buy which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.

What is Oric Pharmaceuticals’s price target?

The average price target for Oric Pharmaceuticals is 19.33. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $25.00 ,the lowest forecast is $15.00. The average price target represents 133.74% Increase from the current price of $8.27.

What do analysts say about Oric Pharmaceuticals?

Oric Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of ORIC?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Oric Pharmaceuticals (ORIC) Stock Forecast & Price Target

ORIC Analyst Ratings

ORIC Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Oric Pharmaceuticals

ORIC Analyst Recommendation Trends

ORIC Financial Forecast

ORIC Earnings Forecast

ORIC Sales Forecast

ORIC Stock Forecast FAQ

Detailed List of Analyst Forecasts